~12 spots leftby Sep 2028

CAR T-Cell Therapy for Esophageal Cancer

Recruiting in Palo Alto (17 mi)
+6 other locations
Geoffrey Y. Ku, MD - MSK ...
Overseen byGeoffrey Y. Ku
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Recruiting
Sponsor: Memorial Sloan Kettering Cancer Center
Must not be taking: Corticosteroids, Immunosuppressives
Disqualifiers: Pregnancy, HIV, Active hepatitis, others
No Placebo Group

Trial Summary

What is the purpose of this trial?

Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory at Memorial Sloan Kettering to be changed (modified) to become MSLN-targeted CAR T cells, the CAR T-cell therapy that participants will receive during the study. Participant study therapy will take about 3-4 weeks.

Will I have to stop taking my current medications?

The trial requires that you complete any systemic therapy at least 7 days before leukapheresis, and immune checkpoint inhibitor therapy must be completed at least 14 days before leukapheresis. You should discuss your current medications with the study team to ensure compliance with these requirements.

What data supports the effectiveness of the treatment M28z1XXPD1DNR CAR for esophageal cancer?

Research shows that CAR-T cell therapy, which is a type of treatment that uses modified immune cells to target cancer, has been effective in reducing tumors in esophageal cancer models. Specifically, CAR-T cells targeting a protein called CD276 have shown promising results in killing cancer cells and shrinking tumors in studies with mice.12345

Is CAR T-Cell Therapy for Esophageal Cancer safe?

The safety of CAR T-Cell Therapy for esophageal cancer specifically isn't detailed, but similar treatments like PD-1 inhibitors have shown manageable safety profiles in esophageal cancer. In studies, serious side effects occurred in some patients, but no treatment-related deaths were reported, and overall safety was considered acceptable.678910

What makes the M28z1XXPD1DNR CAR treatment unique for esophageal cancer?

The M28z1XXPD1DNR CAR treatment is unique because it uses CAR-T cells, a type of cell-based immunotherapy, to target specific proteins on esophageal cancer cells, potentially improving the effectiveness of treatment for solid tumors like esophageal cancer, which traditionally have limited therapeutic options.25111213

Research Team

Geoffrey Y. Ku, MD - MSK ...

Geoffrey Y. Ku

Principal Investigator

Memorial Sloan Kettering Cancer Center

Eligibility Criteria

This trial is for individuals with certain types of cancer affecting the lining of organs, esophagus, or stomach. Participants must have T cells that can be collected and modified in a lab. Specific eligibility details are not provided but typically include factors like age, health status, and prior treatments.

Inclusion Criteria

My doctor expects me to live for at least 4 more months.
I am fully active or can carry out light work.
I am 18 years old or older.
See 14 more

Exclusion Criteria

I have an autoimmune disease treated within the last year.
Baseline pulse oximetry <90% on room air at the screening time point
Deemed to be noncompliant by the study team for administration of a high-risk treatment agent and for close follow-up after treatment as required by the protocol
See 14 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Leukapheresis and CAR T-cell Modification

Participants undergo leukapheresis to collect T cells, which are then modified to become MSLN-targeted CAR T cells

3-4 weeks

Treatment

Participants receive MSLN-targeted CAR T-cell therapy administered through the peritoneal cavity

3-4 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment, including assessment of adverse events

Up to 1 year

Treatment Details

Interventions

  • M28z1XXPD1DNR CAR (CAR T-cell Therapy)
Trial OverviewThe study tests a new therapy where patients' own T cells are engineered to target cancer cells expressing mesothelin (MSLN). These modified T cells (M28z1XXPD1DNR CAR) are then given back to the patient to help fight the cancer.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Participants with Mesothelin-Positive Esophagogastric Adenocarcinoma with Peritoneal CarcinomatosisExperimental Treatment1 Intervention
Participants will be diagnoses with Mesothelin-Positive Esophagogastric Adenocarcinoma with Peritoneal Carcinomatosis

Find a Clinic Near You

Research Locations NearbySelect from list below to view details:
Memorial Sloan Kettering Westchester (Limited Protocol Activities)Harrison, NY
Memorial Sloan Kettering Monmouth (Limited protocol activities)Middletown, NJ
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)Basking Ridge, NJ
Memorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale, NJ
More Trial Locations
Loading ...

Who Is Running the Clinical Trial?

Memorial Sloan Kettering Cancer Center

Lead Sponsor

Trials
1,998
Recruited
602,000+
Lisa M. DeAngelis profile image

Lisa M. DeAngelis

Memorial Sloan Kettering Cancer Center

Chief Medical Officer since 2021

MD from Columbia University

Selwyn M. Vickers profile image

Selwyn M. Vickers

Memorial Sloan Kettering Cancer Center

Chief Executive Officer since 2022

MD from Johns Hopkins University

Findings from Research

A systematic review of 11 randomized controlled trials involving patients with esophageal cancer (EPC) and gastroesophageal junction cancer (GEJC) found that immune checkpoint inhibitors (ICIs) have a similar risk of severe treatment-related adverse events (trAEs) compared to chemotherapy, with a risk ratio of 0.764.
While ICIs were associated with a higher incidence of immune-related adverse events (irAEs) compared to chemotherapy (7.35% vs. 2.25%), the overall rates of these events were considered low and manageable, highlighting the importance of monitoring for specific adverse effects in patients receiving ICIs.
Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials.Zheng, J., Huang, B., Xiao, L., et al.[2023]

References

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. [2022]
Multi-institutional Evaluation of Curative Intent Chemoradiotherapy for Patients With Clinical T1N0 Esophageal Adenocarcinoma. [2022]
Characteristics and response to next-generation sequencing-guided therapy in locally advanced or metastatic esophageal cancer. [2023]
Change in PD-L1 and CD8 Expression after Chemoradiotherapy for Esophageal Squamous Cell Carcinoma. [2022]
Targeting CD276 by CAR-T cells induces regression of esophagus squamous cell carcinoma in xenograft mouse models. [2021]
Profile of treatment-related adverse events of PD-1 blockade-based therapies in advanced esophageal cancer: A systematic review and meta-analysis. [2023]
Addition of camrelizumab to docetaxel, cisplatin, and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma: a phase 1b study. [2021]
PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis. [2022]
Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials. [2023]
10.United Statespubmed.ncbi.nlm.nih.gov
PD-1 inhibitors in esophageal cancer: a systematic review of the oncological outcomes associated with PD-1 blockade and the evolving therapeutic paradigm. [2022]
JAK-STAT Domain Enhanced MUC1-CAR-T Cells Induced Esophageal Cancer Elimination. [2022]
A method for establishing a patient-derived xenograft model to explore new therapeutic strategies for esophageal squamous cell carcinoma. [2022]
EphA2 chimeric antigen receptor-modified T cells for the immunotherapy of esophageal squamous cell carcinoma. [2022]